Investing analyses

# LIFE — Earnings Review Q4 FY25 (Atlas)

> Date: 2026-04-06
> Quarter: Q4 FY2025 (Dec 2025) — First public earnings (IPO Jan 28, 2026)
> Market cap: ~$0.75B | EV/TTM Rev: ~1.1x | Revenue growth: +65.5% YoY (Q4), +52.1% YoY (FY)

## Verdict

Ethos is a rare find: a profitable, 50%+ growth company trading at 1.1x EV/revenue and ~10x GAAP earnings because the stock has been crushed post-IPO (down 37% from $19 to $11.89). The business fundamentals are exceptional — 98% gross margins, 22% GAAP operating margins, Rule of 40 at 88, and a three-sided platform with real network effects in the fragmented $140B+ life insurance market. The lockup overhang (July 2026) and SoftBank's underwater position are creating a dislocation. This is the cheapest high-quality growth company I have seen in the current market. **Conviction: 4/5** — would be 5 if not for carrier concentration risk, limited public track record (1 quarter), and the lockup cliff.

## Qualification Gate

| Criterion | Threshold | Actual | Verdict |
|-----------|-----------|--------|---------|
| Revenue YoY growth | >30% (>40% preferred) | +65.5% Q4, +52.1% FY | **PASS** |
| Gross margin | >60% (>70% preferred) | 98.1% | **PASS** |
| Revenue per quarter | >$50M | $110.1M | **PASS** |
| Data availability | 4+ quarters | 5 quarters | **PASS** |
| Share dilution | <10% annual | ~8.6% (IPO-driven, one-time) | **PASS** |
| GAAP profitability | Improving or positive | Net income $71.2M FY25, +46% YoY | **PASS** |

All gates passed. Notably, LIFE passes every threshold at the *preferred* level, not just the minimum.

## Six-Factor Score

| Factor | Rating | Detail |
|--------|--------|--------|
| Growth | **Strong** | +65.5% YoY Q4, +52.1% FY. Third consecutive year >50%. Q1'26 guide +53-63% YoY. |
| Trajectory | **Mixed** | Volatile intra-year: +66→+58→+34→+53→+65. Re-accelerated H2 but FY26 guide implies deceleration to +32%. Likely conservative first-year guide. |
| Margins | **Exceptional** | 98% gross (asset-light, n

*…truncated*

# LIFE (Ethos) — Earnings Review Update | April 29, 2026

> **WSM | 2026-04-29**
> Pre-Q1-FY26 update (next ER: May 6, 2026). Q4 FY25 already reviewed April 6. This refresh integrates new data: transcript now available, Liberty Mutual white-label deal (April 23), three carrier partnerships in Q1 2026, stock +66% from lows, fresh analyst initiations.
> Prior file: `analyses/LIFE/LIFE_earnings-review_Q4_FY25.md`

---

## Verdict

**Thesis is strengthening — and three weeks ahead of Q1 results, this is no longer just a "broken insurtech mispricing" story.** Liberty Mutual white-labeling Ethos' underwriting engine (April 23) reframes the company from "DTC insurtech with concentration risk" to **"life insurance infrastructure platform powering Top-5 P&C carriers."** Combined with the now-available transcript (high-quality CEO/CFO answers, 7 analyst firms covering, articulate moat), three carrier partnerships in Q1 2026, and management explicitly telegraphing a **~10pp drop in carrier concentration in the upcoming 10-K**, the single biggest existential risk in my April 6 thesis is being actively de-risked.

The stock has rallied 66% from $10.35 lows to $17.17, taking market cap back over $1B. Valuation is no longer "absurdly cheap" — but at **2.1x EV/run-rate revenue, 11x run-rate P/E, PEG of 0.17x for a 65% YoY grower with 23% EBITDA margins and a brand-new $1B+ partnership**, it's still inexpensive by any growth-investor standard. **Nuf said.**

**→ I'm sizing now, not waiting for May 6. Initiate 3% starter position pre-print.** Add to 5-7% on a Q1 beat-and-raise. Run for the hills if Q1 misses guidance OR third-party channel posts a second sequential decline.

---

## What's Changed Since April 6

| Item | April 6 Status | April 29 Update | Impact on Thesis |
|------|----------------|-----------------|------------------|
| Earnings transcript | Unavailable (flagged red flag) | Full transcript with 7 analyst Q&A | **Strengthens** — high-quality, articulate CEO answers |

*…truncated*

# LIFE — Ethos Technologies — Stock Analysis
## Philip A. Fisher Framework

> **Date:** 2026-04-15
> **Stock Price:** ~$14.69 (Apr 14, 2026) | Shares: 62.9M | Market Cap: ~$927M | EV: ~$816M
> **Atlas Baseline:** Earnings review (2026-04-06) — Conviction 4/5, "cheapest high-quality growth company"
> **Prior Phil Analysis:** Earnings review (2026-04-06) — Buy (partial position), 10/15 points pass

---

## Prior Beliefs

I initiated coverage of Ethos Technologies ten days ago, on the strength of its Q4 FY2025 earnings. At that time the stock traded at approximately $11.89 — down 37% from its January IPO at $19. I concluded that Ethos was "fortunate because it is able," warranting a partial position with the intention of sizing up after the Q1 2026 earnings call on May 6 would permit me to assess management transparency under questioning.

In the intervening period, the stock has risen 24% to $14.69. The fundamental picture has not changed — no new earnings, no new management disclosures — but the scuttlebutt has deepened in ways that both strengthen and complicate the thesis. I return to the company now not because the price has moved, but because additional competitive intelligence has emerged that demands a more complete analysis than an earnings review could provide.

---

## Scuttlebutt Mosaic

The scuttlebutt on Ethos has matured since my April 6 earnings review. I now have two full rounds of systematic research across all seven categories, and the pattern that emerges is unusually crisp for a company with only one public quarter of history.

### What Customers Reveal — Point 4 (Sales Organization)

The customer evidence remains the strongest pillar of the investment case. Trustpilot holds at 4.8 out of 5 across 740-plus reviews. Google Reviews at 4.7. BBB accreditation at A+. The Net Promoter Score of 70, against an industry average of 14, is not a marginal improvement — it represents a categorical transformation of the customer experience in a sector that has b

*…truncated*

# LIFE — Ethos Technologies — Earnings Review Q4 FY25

> Date: 2026-04-06
> Quarter: Q4 FY2025 (Dec 2025) — First public earnings call (IPO Jan 28, 2026)
> Market cap: ~$748M | Price: $11.89 | Shares: 62.9M
> EV: ~$430M (net cash ~$318M incl. IPO proceeds) | EV/TTM Rev: 1.1x

---

## Prior Beliefs

I haven't written about LIFE specifically — this is my first look. So rather than formal prior beliefs, let me state what I was looking for walking in:

1. **Revenue growth sustainability.** For a 50%+ grower, I want to see evidence the rate is holding, not just a one-quarter spike.
2. **Margin structure.** Insurtech is a broad label. I needed to understand whether this is an underwriter (capital-heavy) or a distributor (capital-light). That distinction matters enormously.
3. **Unit economics trajectory.** Is contribution margin expanding as the platform scales, or is growth being bought with marketing spend?
4. **Valuation sanity.** At an EV/Revenue of 1.1x for a 50% grower, I expected to find something wrong. Companies don't trade this cheap without a reason.
5. **Management credibility.** First public quarter — no track record to assess. I expected this would be the biggest gap.

---

## The Numbers

| | Q424 | Q125 | Q225 | Q325 | Q425 |
| | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|---|---|---|---|---|---|
| Revenue ($M) | 66.5 | ~89.0 | ~94.0 | ~95.0 | **110.1** |
| YoY % | +66% | +58% | +34% | +53% | **+65.5%** |
| QoQ % | — | +33.8% | +5.6% | +1.1% | **+15.9%** |
| Gross Margin % [GAAP] | 97.7% | ~98% | ~98% | ~98% | **98.1%** |
| Op Margin % [GAAP] | 18.8% | — | — | — | **22.2%** |
| Net Margin % [GAAP] | 14.3% | — | — | — | **22.3%** |
| Adj EBITDA ($M) | ~15 | ~19 | ~21 | ~24 | **25.8** |
| EBITDA Margin % | ~22% | ~21% | ~22% | ~25% | **23%** |
| Policies Activated | 38,515 | 46,283 | 49,219 | 48,122 | **54,714** |
| ARPU ($) | 1,727 | 1,920 | 1,906 | 1,972 | **2,012** |
| Contribution Margin % | 39.1% | 41.6% | 40.4% | 42.1% | **42.9%** |
| Direct Rev ($M

*…truncated*

# LIFE — Ethos Technologies — Earnings Review Q4 FY25

> Date: 2026-04-06
> Quarter: Q4 FY2025 (Dec 2025) — FIRST PUBLIC EARNINGS (IPO Jan 28, 2026)
> Price: $11.89 | Shares: 62.9M | Market Cap: ~$748M | EV: ~$430M | EV/TTM Rev: 1.1x

## Verdict: Blowout Numbers, But I Have Concerns

Look, the numbers here are really, really impressive. Revenue up 65% year over year in Q4! 98% gross margins! GAAP profitable! A Rule of 40 score of 88! And the stock is trading at just 1.1x EV/revenue??? That's just preposterous for a company growing this fast and this profitably.

But — and this is a big but — I have real concerns about carrier concentration. When 3 carriers represent something like 88-98% of your revenue, you are NOT a master of your own fate. You are dependent on a handful of powerful partners who could renegotiate your commission rates or walk away. I've seen this movie before, and it doesn't always end well.

Still, the trajectory is unmistakable, the valuation is absurdly cheap, and the business model — earning commissions with zero balance sheet risk, at 98% gross margins — is genuinely unique. This deserves a position, even if a cautious one.

**Thesis: New Coverage — Cautiously Bullish. Watch carrier concentration and Q1 guidance beat.**

## The Numbers

| | Q424 | Q125 | Q225 | Q325 | Q425 |
| | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|---|---|---|---|---|---|
| Revenue ($M) | 66.5 | ~89.0 | ~94.0 | ~95.0 | **110.1** |
| YoY % | +66% | +58% | +34% | +53% | **+65.5%** |
| QoQ % | — | +33.8% | +5.6% | +1.1% | **+15.9%** |
| Gross Margin [GAAP] | 97.7% | ~98% | ~98% | ~98% | **98.1%** |
| Op Margin [GAAP] | 18.8% | — | — | — | **22.2%** |
| Adj EBITDA ($M) | ~15 | ~19 | ~21 | ~24 | **25.8** |
| EBITDA Margin | ~22% | ~21% | ~22% | ~25% | **23%** |
| Policies Activated | 38,515 | 46,283 | 49,219 | 48,122 | **54,714** |
| ARPU ($) | 1,727 | 1,920 | 1,906 | 1,972 | **$2,012** |
| Contribution Margin | 39.1% | 41.6% | 40.4% | 42.1% | **42.9%** |

*Q1-Q3 FY25 ap

*…truncated*